SCHEMBL4861054

SCHEMBL4861054

CCOc1[c]cc2c(Nc3ccc(OCc4ccccn4)c(Cl)c3)nc(C(N)=O)nc2c1

nearest known ligand 0.54

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
ERBB2 P04626 14/20 0.54
EGFR P00533 11/20 0.54
AURKA O14965 1/20 0.54
RPS6KB1 P23443 1/20 0.54
LCK P06239 1/20 0.53
STK3 Q13188 2/20 0.48
STK4 Q13043 2/20 0.48
KCNH2 Q12809 3/20 0.48
ERBB3 P21860 1/20 0.47
ERBB4 Q15303 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2255343 0.94 AURKA (0.54) ERBB2EGFRAURKARPS6KB1LCK
SCHEMBL4868107 0.93 AURKA (0.51) ERBB2EGFRAURKARPS6KB1LCK
SCHEMBL5122526 0.92 ERBB2 (0.51) ERBB2EGFRAURKARPS6KB1LCK
SCHEMBL4865132 0.92 AURKA (0.52) ERBB2EGFRAURKARPS6KB1LCK
SCHEMBL5125233 0.91 AURKA (0.51) ERBB2EGFRAURKARPS6KB1LCK
SCHEMBL4864883 0.90 AURKA (0.57) ERBB2EGFRAURKARPS6KB1LCK
SCHEMBL4868089 0.90 AURKA (0.52) ERBB2EGFRAURKARPS6KB1LCK
SCHEMBL4867809 0.89 AURKA (0.53) ERBB2EGFRAURKARPS6KB1LCK
SCHEMBL4864442 0.89 AURKA (0.55) ERBB2EGFRAURKARPS6KB1LCK
SCHEMBL4857286 0.88 AURKA (0.53) ERBB2EGFRAURKARPS6KB1LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1844022-B1 QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF HANMI SCIENCE CO LTD (KR) 2013-08-14 EP claimed
JP-2008525522-A 2008-07-17 JP claimed
US-20080009509-A1 Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof HANMI PHARM CO., LTD (KR) 2008-01-10 US claimed
EP-1844022-A1 QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF Hanmi Pharm. Co., Ltd. (KR) 2007-10-17 EP claimed
WO-2006071017-A1 QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF HANMI PHARM. CO., LTD. (KR) 2006-07-06 WO claimed
EP-1844022-B1 QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF HANMI SCIENCE CO LTD (KR) 2013-08-14 EP disclosed
US-20080009509-A1 Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof HANMI PHARM CO., LTD (KR) 2008-01-10 US disclosed
EP-1844022-A1 QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF Hanmi Pharm. Co., Ltd. (KR) 2007-10-17 EP disclosed
WO-2006071017-A1 QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF HANMI PHARM. CO., LTD. (KR) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009509-A1 Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof MKI67, NQO2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 ERBB2 1693/4885EGFR 1400/4885AURKA 177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.